Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 5/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | AURKA | O14965 | 3/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.41 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.41 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | FES | P07332 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3696493 | 0.94 | FGFR2 (0.46) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL15663316 | 0.90 | FGFR2 (0.48) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL2211255 | 0.90 | FGFR2 (0.60) | FGFR2KDREGFRRIPK2EPHB2 | |
| SCHEMBL3694327 | 0.89 | FGFR2 (0.48) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL3701420 | 0.88 | FGFR2 (0.47) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL2209361 | 0.88 | FGFR2 (0.55) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL2965225 | 0.86 | MAPT (0.41) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL2210453 | 0.86 | FGFR2 (0.44) | FGFR2KDRAURKAAURKBTPX2 | |
| SCHEMBL3713406 | 0.85 | TGFBR1 (0.40) | FGFR2KDRAURKAAURKBULK1 | |
| SCHEMBL2209742 | 0.83 | FGFR2 (0.60) | FGFR2KDRPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2012-05-17 | — | — | US | claimed |
| EP-2137177-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122847-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, CDK1 | FGFR2 334/4885KDR 644/4885AURKA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.